Online inquiry

IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7124MR)

This product GTTS-WQ7124MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000233.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3973
UniProt ID P22888
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ7124MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8636MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ7223MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ9296MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ5746MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ13423MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ2842MR IVTScrip™ mRNA-Anti-NGF, AMG-403(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-403
GTTS-WQ8572MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ5091MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAM-3001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW